AbbVie Receives U.S. FDA Approval of MAVYRET(TM) (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT 1-6) in as Short as 8 Weeks; - MAVYRET is a new 8-week, pan-genotypic treatment for hepatitis C patients withou

Media coverage

• Title	AbbVie Receives U.S. FDA Approval of MAVYRET(TM) (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT 1-6) in as Short as 8 Weeks; - MAVYRET is a new 8-week, pan-genotypic treatment for hepatitis C patients withou
  Media name/outlet	PR Newswire
  Country	United States
  Date	8/3/17
  Persons	Fred Poordad

• Title	AbbVie Receives U.S. FDA Approval of MAVYRET(TM) (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT 1-6) in as Short as 8 Weeks; - MAVYRET is a new 8-week, pan-genotypic treatment for hepatitis C patients withou
  Media name/outlet	PR Newswire
  Country	United States
  Date	8/3/17
  Persons	Fred Poordad